April 5, 2021

S2-E17.1 – Questions in Screening: Do liquid tests bring better value than elastography?

Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversation to consider what "efficiency" means in the context of patient diagnosis and whether "less expensive" is always more efficient.

In this conversation, he questions whether positioning a second blood-based test between FIB-4 and FibroScan improves cost-effectiveness or, simple diagnosis. One Spoiler Alert: The Leeds data suggests that efficient screening processes for NAFLD and alcoholic liver disease may differ significantly. Stephen Harrison notes that polygenetic testing will introduce an entirely new set of issues to this question. There’s a lot to consider here.

TOPICS: cirrhosis, EchoSens, ELF, FIB-4, FibroScan, non-invasive liver testing, Nordic Biosciences, Perspectum Diagnostics, Siemens Healthineers, Alcohol-related liver disease, negative predictive value, positive predictive value,

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.

S2-E17.1 – Questions in Screening: Do liquid tests bring better value than elastography?

Listen Now

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.

S2-E17.1 – Questions in Screening: Do liquid tests bring better value than elastography?

Episode Categories

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.